Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

GARDASIL™ (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18) Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions and for prevention of genital warts in males and females 9-26 years of age.

HPV vaccine may prevent anal cancer